This company has been acquired
GreenLight Biosciences Holdings Balance Sheet Health
Financial Health criteria checks 4/6
GreenLight Biosciences Holdings has a total shareholder equity of $21.9M and total debt of $24.5M, which brings its debt-to-equity ratio to 111.6%. Its total assets and total liabilities are $113.7M and $91.8M respectively.
Key information
111.6%
Debt to equity ratio
US$24.48m
Debt
Interest coverage ratio | n/a |
Cash | US$32.35m |
Equity | US$21.94m |
Total liabilities | US$91.75m |
Total assets | US$113.69m |
Recent financial health updates
No updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Financial Position Analysis
Short Term Liabilities: GRNA's short term assets ($37.7M) exceed its short term liabilities ($31.2M).
Long Term Liabilities: GRNA's short term assets ($37.7M) do not cover its long term liabilities ($60.6M).
Debt to Equity History and Analysis
Debt Level: GRNA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GRNA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRNA has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: GRNA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.